A Randomized Placebo-controlled Single Center Pilot Study of the Safety and Efficacy of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata
Phase of Trial: Phase II
Latest Information Update: 17 Apr 2017
At a glance
- Drugs Tralokinumab (Primary)
- Indications Alopecia areata
- Focus Pharmacodynamics
- 11 Apr 2017 Planned End Date changed from 1 Oct 2017 to 1 Apr 2018.
- 11 Apr 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Apr 2018.
- 23 Feb 2016 New trial record